{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:50:20Z","timestamp":1777355420682,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T00:00:00Z","timestamp":1206403200000},"content-version":"vor","delay-in-days":3828,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Australian and New Zealand Journal of Medicine"],"published-print":{"date-parts":[[1997,10]]},"abstract":"<jats:p><jats:bold>Abstract<\/jats:bold>  <jats:italic>Background<\/jats:italic>: Hepatitis C viral (HCV) infection poses a major health problem for Australia. Currently interferon therapy is approved only for people with chronic infection, yet the literature contains a number of studies that show that there is a better response to interferon in symptomatic acute HCV.<\/jats:p><jats:p> <jats:italic>Aim:<\/jats:italic> To review the response to interferon therapy in acute HCV by way of meta\u2010analysis.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>: This study was a retrospective review of the data on the use of interferon therapy in acute HCV. The meta\u2010analysis was performed using the methods of DerSimonian and Laird. Data were presented by calculating the risk difference which estimated efficacy by calculating the proportion of patients in treatment groups who responded better (0 to +1.0) or worse (0 to \u22121.0) than untreated control groups.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>: A meta\u2010analysis of six studies on the use of 3MU of interferon alpha 2b (IFN\u2010a2b) three times a week for six to 24 weeks showed a significant response as measured by long term (&gt;12 months) normalisation of alanine aminotransferase (ALT) and clearance of HCV RNA (as measured by polymerase chain reaction). The risk of difference was +0.31 (95% CI of +0.19 to +0.43,<jats:italic>p<\/jats:italic>&lt;0.01) and +0.33 (95% CI of +0.08 to +0.58, <jats:italic>p<\/jats:italic>&lt;0.001) respectively.<\/jats:p><jats:p>Slightly better results were seen with daily doses of 3MU of interferon beta (IFN\u2010p) given intravenously over four to seven weeks. This produced a risk difference of +0.57 (95% CI of +0.26 to +0.88, <jats:italic>p<\/jats:italic>&lt;0.02) for normalisation of ALT and +0.83 (95% CI of +0.61 to 1.00,<jats:italic>p<\/jats:italic>&lt;0.001) for clearance of HCV.<\/jats:p><jats:p>Results for higher daily doses of both IFN \u03b1 and \u03b2 were limited to a few studies and most were uncontrolled. 6MU of IFN\u2010a2b three times a week for 16 to 24 weeks produced a risk difference of +0.53 (95% CI +0.17 to +0.89, <jats:italic>p<\/jats:italic>&lt;0.05) for normalisation of ALT and +0.44 (95% CI +0.06 to +0.82) for clearance of HCV RNA. Results with 6MU daily for eight weeks of IFN\u2010\u03b2 in an uncontrolled study, showed up to 90% patients cleared HCV long term. Preliminary results with 10MU of IFN\u2010a2b daily for four to six weeks also showed long term clearance of HCV RNA and normalisation of ALT in 90%o of treated patients.<\/jats:p><jats:p> <jats:italic>Conclusion<\/jats:italic>: Short term (six weeks to six months) treatment of symptomatic acute HCV with interferon (both <jats:italic>a<\/jats:italic> and (3) produced a better long term response rate than prolonged therapy (&gt; 12 months) in chronic HCV. Daily doses of 6MU and 10MU produced better responses than 3MU but more studies are needed to determine the optimum regime.<\/jats:p>","DOI":"10.1111\/j.1445-5994.1997.tb00985.x","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T09:43:50Z","timestamp":1206438230000},"page":"611-618","source":"Crossref","is-referenced-by-count":25,"title":["Interferon therapy for acute hepatitis C viral infection \u2010 a review by meta\u2010analysis"],"prefix":"10.1111","volume":"27","author":[{"given":"J. W.","family":"Quin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,25]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"384","article-title":"for the Communication Diseases Network Australia and New Zealand. Enhanced Surveillance for incident cases of hepatitis C in Australia 1995","volume":"20","author":"Andrews R","year":"1996","journal-title":"Comm Dis Intell"},{"key":"e_1_2_1_3_2","unstructured":"LeaderS.The public health challenge of hepatitis C. First Australian Conference on Hepatitis C.March 1997 Sydney."},{"key":"e_1_2_1_4_2","unstructured":"CroftsN AitkenC.Hepatitis C in a cohort of Victorian injecting drug users. First Australian Conference on Hepatitis C Sydney \u2010 abstracts.1997;32\u20133."},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","unstructured":"SodeyamaT KiyosawaK UrushiharaAet al.Transmission of hepatitis C virus through needlestick accidents in health care workers.Viral hepatitis and liver disease.1994;459\u201362.","DOI":"10.1007\/978-4-431-68255-4_117"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1996.tb00755.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-367"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160502"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613001"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb04677.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02087880"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365549309008497"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.1.148"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212313272702"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701303360507"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02088245"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840150504"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","unstructured":"ColomboM LamperticoP RumiM.Multicentre randomised controlled trial of recombinant interferon alfa\u20102b in patients with acute non A non B\/type C hepatitis after transfusion.Gut1993;S141.","DOI":"10.1136\/gut.34.2_Suppl.S141"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","unstructured":"TassopoulosNC KoutelouMG PapatheodoridisGet al.Recombinant human interferon alfa\u20102b treatment for acute non\u2010A non\u2010B hepatitis.Gut1993;SI30\u20132.","DOI":"10.1136\/gut.34.2_Suppl.S130"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190105"},{"key":"e_1_2_1_21_2","first-page":"409","article-title":"A report on therapy of interferon A\u20102b in patients with acute hepatitis","volume":"32","author":"Li XW","year":"1993","journal-title":"(Chinese) Chin J Int Med"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","unstructured":"GenescaJ EstebanJI QuerJet al.Hepatitis C virus makers in patients with acute post\u2010transfusion hepatitis treated with interferon alfa\u20102b.Gut1993;S62\u20133.","DOI":"10.1136\/gut.34.2_Suppl.S62"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(94)80246-7"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01716714"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","unstructured":"AlbertiA ChemelloL BelussiFet al.Outcome of acute hepatitis C and role of alpha interferon therapy.Viral hepatitis and liver diseases.1994;604\u20136.","DOI":"10.1007\/978-4-431-68255-4_157"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","unstructured":"OmataM TakanoS.A randomised controlled trial of Interferon\u2010P treatment of acute hepatitis C.Viral hepatitis and liver disease.1994;601\u20133.","DOI":"10.1007\/978-4-431-68255-4_156"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90130-9"},{"key":"e_1_2_1_28_2","first-page":"1847","article-title":"Interferon therapy for acute hepatitis C; changes in serum makers associated with HCV and clinical effects","volume":"52","author":"Fukui S","year":"1994","journal-title":"Jap J Clin Med"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_1_30_2","first-page":"90","volume-title":"Meta\u2010analysis, decision analysis and cost\u2010effectiveness analysis: Methods for quantitative synthesis in medicine","author":"Petitti DB","year":"1994"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8536870"}],"container-title":["Australian and New Zealand Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.1997.tb00985.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.1997.tb00985.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T22:48:21Z","timestamp":1698446901000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.1997.tb00985.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997,10]]}},"alternative-id":["10.1111\/j.1445-5994.1997.tb00985.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.1997.tb00985.x","archive":["Portico"],"relation":{},"ISSN":["0004-8291"],"issn-type":[{"value":"0004-8291","type":"print"}],"subject":[],"published":{"date-parts":[[1997,10]]}}}